NTRK2 and Ataxia: Another anticipated ADE is weight gain, due to the vital role of NTRK2 in controlling energy balance and appetite (An et al., 2020; Houtz et al., 2021) Consistently, at the PT level, we also identified several common, drug-related on-target adverse reactions, including dizziness, constipation, ataxia, weight increased, balance disorder, and dysgeusia.